BioTuesdays

Tag - Roth

Arvinas

Roth starts Arvinas at buy; PT $35

Roth Capital Partners initiated coverage of Arvinas (NASDAQ:ARVN) with a “buy” rating and $35 price target. The stock closed at $28.38 on Nov. 13. Analyst Zegbeh Jallah writes that Arvinas is one of the leaders in the...

Bicycle Therapeutics

Roth starts Bicycle Therapeutics at buy; PT $17

Roth Capital Partners launched coverage of Bicycle Therapeutics (NASDAQ:BCYC) with a “buy” rating and $17 price target. The stock closed at $8.61 on Nov. 13. Bicycle is developing peptides that may be able to deliver a...

Harpoon Therapeutics

Roth starts Harpoon Therapeutics at buy; PT $25

Roth Capital Partners launched coverage of Harpoon Therapeutics (NASDAQ:HARP) with a “buy” rating and price target of $25. The stock closed at $13.51 on Nov. 13. Analyst Zegbeh Jallah writes that Harpoon has a next...

Allena Pharmaceuticals

Roth sticking with Allena Pharma despite selloff

Roth Capital Partners believes Allena Pharmaceuticals (NASDAQ:ALNA) is getting “unnecessarily punished” on Nov. 7, despite positive URIROX-1 top-line study data, which included a high placebo response, smaller treatment...

Daxor

Roth starts Daxor at neutral; PT $18

Roth Capital Partners launched coverage of Daxor (NYSE American:DXR) with a “neutral” rating and $18 price target. The stock closed at $9.62 on Sept. 27. Daxor is an investment management company, with a medical device...

Roth starts Myomo at buy; PT $9

Roth Capital Partners initiated coverage of Myomo (NYSE American:MYO) with a “buy” rating and $9 price target. The stock closed at $4.15 on March 8.

Subscribe

Sign up to our weekly BioTuesdays newsletter.